Search Results - "Storrer, CE"
-
1
Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients
Published in Journal of clinical oncology (20-10-2005)“…E75 is an immunogenic peptide from the HER2/neu protein that is highly expressed in breast cancer. We are conducting a clinical trial of an E75 +…”
Get full text
Journal Article -
2
Spontaneous formation of germinal centers in autoimmune mice
Published in Journal of leukocyte biology (01-10-2001)“…The mechanisms of autoantibody production are not well understood. Germinal centers (GC) may be important sites of immune disregulation in autoimmune diseases…”
Get full text
Journal Article -
3
Vaccination with a HER2/ neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer
Published in Surgery (01-03-2006)“…We are conducting clinical vaccine trials with the HER2/ neu peptide, E75, in patients with breast cancer. The purpose of this study was to demonstrate clonal…”
Get full text
Journal Article -
4
Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients
Published in Clinical cancer research (15-10-2005)“…Purpose: The E75 peptide is an immunogenic peptide from the HER-2/ neu protein that is substantially expressed in prostate cancer. We are conducting a clinical…”
Get full text
Journal Article -
5
Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides
Published in Breast cancer research and treatment (01-07-2005)“…The recently reported FACS-based CD107 assay has been used in human HIV and CMV antigen models as well as in the ex vivo analysis of tumor cytolytic T cells in…”
Get full text
Journal Article -
6
Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients
Published in Clinical cancer research (15-01-2006)“…Purpose: We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their clinicopathologic variables and…”
Get full text
Journal Article -
7
Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients
Published in Journal of clinical immunology (01-07-2004)“…HER2/neu is a proto-oncogene and a member of the epidermal growth factor receptor family of proteins that is overexpressed in numerous types of human cancer…”
Get full text
Journal Article -
8
Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex registered technology
Published in Oncology reports (01-03-2007)“…We used the Luminex assay to compare serum cytokine profiles of breast cancer patients (BCa) to healthy controls, node-positive (NP) patients to node-negative…”
Get full text
Journal Article -
9
Further characterization of the autoantibody response of Palmerston North mice
Published in Journal of clinical immunology (1999)“…PN mice spontaneously develop, with age, a lupus-like disease. The present study further evaluated autoantibody production in female PN mice. As early as 1…”
Get full text
Journal Article -
10
Vasculitis in the Palmerston North mouse model of lupus: Phenotype and cytokine production profile of infiltrating cells
Published in Arthritis and rheumatism (01-03-1999)“…Objective To define the phenotype of cells in the perivascular and vascular infiltrates of Palmerston North (PN) mice and the cytokines that those cells…”
Get full text
Journal Article